New clinical trial design in precision medicine: discovery, development and direction
XP Duan, BD Qin, XD Jiao, K Liu, Z Wang… - Signal Transduction and …, 2024 - nature.com
In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …
certain disease are complex and different from each other. Due to the underestimation of the …
The current status and future of targeted-immune combination for hepatocellular carcinoma
L Hao, S Li, F Ye, H Wang, Y Zhong, X Zhang… - Frontiers in …, 2024 - frontiersin.org
Hepatocellular carcinoma (HCC) is one of the most common cancers and the third leading
cause of death worldwide. surgery, transarterial chemoembolization (TACE), systemic …
cause of death worldwide. surgery, transarterial chemoembolization (TACE), systemic …
[HTML][HTML] Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective …
L Zhang, J Feng, T Kuang, D Chai, Z Qiu… - International …, 2023 - Elsevier
Objective We conducted the first meta-analysis to identify the predictive significance of
baseline blood biomarkers (such as neutrophil to lymphocyte ratio (NLR), early alpha …
baseline blood biomarkers (such as neutrophil to lymphocyte ratio (NLR), early alpha …
Sorafenib suppresses radioresistance and synergizes radiotherapy-mediated CD8+ T cell activation to eradicate hepatocellular carcinoma
CC Cheng, AS Ho, CL Peng, J Chang, ZL Sie… - International …, 2022 - Elsevier
Radiotherapy (RT) is applied to eradicate tumors in the clinic. However, hepatocellular
carcinoma (HCC) exhibits resistance against RT. It is demonstrated that RT directly inhibits …
carcinoma (HCC) exhibits resistance against RT. It is demonstrated that RT directly inhibits …
Evaluating the benefits of TACE combined with lenvatinib plus PD-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus
X Zou, Q Xu, R You, G Yin - Advances in Therapy, 2023 - Springer
Introduction This study evaluated the efficacy and safety of transarterial chemoembolization
(TACE) combined with lenvatinib plus programmed death (PD)-1 inhibitor (TACE-LP) versus …
(TACE) combined with lenvatinib plus programmed death (PD)-1 inhibitor (TACE-LP) versus …
Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor‐Initiating Stem‐Like Cells
CL Chen, JC Hernandez, DB Uthaya Kumar… - Advanced …, 2023 - Wiley Online Library
A critical barrier to effective cancer therapy is the improvement of drug selectivity, toxicity,
and reduced recurrence of tumors expanded from tumor‐initiating stem‐like cells (TICs). The …
and reduced recurrence of tumors expanded from tumor‐initiating stem‐like cells (TICs). The …
[HTML][HTML] Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma
S Wei, F Wei, M Li, Y Yang, J Zhang, C Li… - Biomedicine & …, 2023 - Elsevier
Sorafenib, a multi-kinase inhibitor, has been approved for cancer treatment for decades,
especially hepatocellular carcinoma (HCC). Although sorafenib produced substantial …
especially hepatocellular carcinoma (HCC). Although sorafenib produced substantial …
Adverse events of PD-(L) 1 inhibitors plus anti-VEGF (R) agents compared with PD-(L) 1 inhibitors alone for cancer patients: a systematic review and meta-analysis
Q Tang, D Wu, H Huang, H Fang, Y Wu… - Frontiers in …, 2023 - frontiersin.org
Background: Anti-PD-(L) 1 antibody monotherapy or in combination with VEGF (R) blockade
has been applied widely for cancer treatment. Whether combination therapy increases irAEs …
has been applied widely for cancer treatment. Whether combination therapy increases irAEs …
[HTML][HTML] Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma
K Oura, A Morishita, T Tadokoro, K Fujita… - International Journal of …, 2024 - mdpi.com
Systemic therapy for unresectable hepatocellular carcinoma (HCC) has progressed with the
development of multiple kinases, such as vascular endothelial growth factor (VEGF) …
development of multiple kinases, such as vascular endothelial growth factor (VEGF) …
Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis
F Xian, C Wu, G Zhang, G Xu - Medicine, 2022 - journals.lww.com
Background: This study aimed to compare the efficacy and safety of immune checkpoint
inhibitors (ICIs) combined with antiangiogenic agents in patients with unresectable …
inhibitors (ICIs) combined with antiangiogenic agents in patients with unresectable …